智慧科技

  • Home
  • About
    • About the Journal
    • Contact
  • Article
    • Current
    • Archives
  • Submissions
  • Editorial Team
  • Announcements
Register Login

ISSN

3082-8201(Oline)

3082-821X(Print)

Article Processing Charges (APCs)

SGD$600

Publication Frequency

Bi-Monthly

PDF全文下载

Published

2026-09-07

Issue

Vol 3 No 4 (2026): Published

Section

Articles

How to Cite

  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver

  • Download Citation
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX

指南导向的人工智能辅助TI-RADS分级在甲状腺结节风险分层与规范化管理中的应用价值

马 诺

宁夏医科大学第一临床医学院

黄 飞

宁夏医科大学第一临床医学院

张 渝悦

宁夏医科大学中医学院

张 晴晴

宁夏医科大学第三临床医学院

董 文阅

宁夏医科大学口腔医学院


DOI: https://doi.org/10.59429/zhkj.v3i4.15162


Keywords: 甲状腺结节;TI-RADS;人工智能;超声;临床决策支持;随访管理


Abstract

甲状腺结节检出率持续升高,如何在避免漏诊恶性结节的同时减少低风险结节过度检查和过度干预,已成为 超声医学、内分泌、甲状腺外科和基层医疗共同面对的现实问题。甲状腺影像报告和数据系统通过标准化超声征象 描述和恶性风险分层,为甲状腺结节诊疗提供了重要依据,但其临床应用仍受操作者经验、图像质量、报告规范、 穿刺阈值理解和随访执行等因素影响。近年来,深度学习、机器学习、医学影像数据集和临床决策支持系统的发展, 为 TI-RADS 自动化分级、风险再评估、随访提醒和真实世界数据利用提供了新路径。本文围绕甲状腺结节规范化 管理需求,综述 TI-RADS 体系的临床价值与局限、人工智能辅助超声分析的技术进展、从智能分级到决策支持的 转化路径、随访闭环与数据治理要求,并讨论外部验证、可解释性、责任边界、隐私保护和前瞻性评价等关键问题。 未来,人工智能辅助 TI-RADS 不应被定位为替代医生的诊断工具,而应作为指南落地、质量控制和分层管理的辅 助工具,在医生主导下服务于甲状腺结节的规范诊疗和长期管理。


References

[1] Lyu Z, Li G, Liu Y, et al. Global burden of thyroid canc%er in 2022: Incidence and mortality estimates from GLOBOCAN[J]. Chinese Medical Journal, 2024, 137(21): 2567-2576. DOI:10.1097/CM9.0000000000003284.

[2] 中华医学会内分泌学分会,中华医学会外科学分会甲状腺及代谢外科学组,中国抗癌协会头颈肿瘤专业委员会,等. 甲状腺结节和分化型甲状腺癌诊治指南(第二版)[J]. 国际内分泌代谢杂志,2023, 43(2):149-194. DOI:10.3760/cma.j.cn311282-20221023-00589-1.

[3] Zhou J Q, Yin L X, Wei X, et al. 2020 Chinese guidelines for ultrasound malignancy risk stratification of thyroid nodules: the C-TIRADS[J]. Endocrine, 2020, 70(2): 256-279. DOI:10.1007/s12020-020-02441-y.

[4] Durante C, Hegedüs L, Czarniecka A, et al. 2023 European Thyroid Association clinical practice guidelines for thyroid nodule management[J]. European Thyroid Journal, 2023, 12(5): e230067. DOI:10.1530/ETJ-23-0067.

[5] Piticchio T, Russ G, Radzina M, Frasca F, Durante C, Trimboli P. Head-to-head comparison of American, European, and Asian TIRADSs in thyroid nodule assessment: systematic review and meta-analysis[J]. European Thyroid Journal, 2024, 13(2): e230242. DOI:10.1530/ETJ-23-0242.

[6] Zhan J, Zhang J, Zhu S, Ni L, Zhang C, Hu J. Diagnostic performance of ultrasound characteristics-based artificial intelligence models for thyroid nodules: a systematic review and meta-analysis[J]. Frontiers in Oncology, 2025, 15: 1614603. DOI:10.3389/fonc.2025.1614603.

[7] Ni J, You Y, Wu X, Chen X, Wang J, Li Y. Performance evaluation of deep learning for the detection and segmentation of thyroid nodules: systematic review and meta-analysis[J]. Journal of Medical Internet Research, 2025, 27: e73516. DOI:10.2196/73516.

[8] Hou X, Hua M, Zhang W, et al. An ultrasonography of thyroid nodules dataset with pathological diagnosis annotation for deep learning[J]. Scientific Data, 2024, 11: 1272. DOI:10.1038/s41597-024-04156-5.

[9] Vasey B, Nagendran M, Campbell B, et al. Reporting guideline for the early stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE-AI[J]. BMJ, 2022, 377: e070904. DOI:10.1136/bmj-2022-070904.

[10] Collins G S, Dhiman P, Andaur Navarro C L, et al. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods[J]. BMJ, 2024, 385: e078378. DOI:10.1136/bmj-2023-078378.



ISSN: 3082-8201
21 Woodlands Close #02-10 Primz Bizhub Singapore 737854

Email:editorial_office@as-pub.com